Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2020.3537
Abstract: Importance The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. Objective To assess the association of adjuvant chemotherapy with overall… read more here.
Keywords: chemotherapy; adjuvant chemotherapy; treatment; pancreatic cancer ... See more keywords
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer
Sign Up to like & getrecommendations! Published in 2020 at "European Radiology"
DOI: 10.1007/s00330-020-07134-8
Abstract: Objectives To identify multiparametric MRI biomarkers to predict the tumor response to neoadjuvant FOLFIRINOX therapy in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Methods From May 2016 to March… read more here.
Keywords: folfirinox therapy; mri; response; neoadjuvant folfirinox ... See more keywords
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American College of Surgeons"
DOI: 10.1097/xcs.0000000000000212
Abstract: BACKGROUND There is increased use of neoadjuvant fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in the management of localized pancreatic ductal adenocarcinoma (PDAC), yet there are few validated biomarkers of treatment response. STUDY DESIGN Consecutive patients… read more here.
Keywords: localized pancreatic; ductal adenocarcinoma; neoadjuvant folfirinox; pancreatic ductal ... See more keywords
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Non-Metastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American College of Surgeons"
DOI: 10.1097/xcs.0000000000000499
Abstract: BACKGROUND Neoadjuvant FOLFIRINOX is increasingly utilized in the management of pancreatic ductal adenocarcinoma (PDAC). However, neoadjuvant therapy is associated with toxicity, possible disease progression, and biopsy and biliary-related complications that may preclude operative exploration. Data… read more here.
Keywords: neoadjuvant folfirinox; exploration; adenocarcinoma; non metastatic ... See more keywords